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Background: Dramatic advances in ventricular assist device (VAD) design and patient management have 
made mechanical circulatory support an attractive therapeutic option for the growing pool of elderly heart 
failure patients.
Methods: A literature review of all relevant studies was performed. No time or language restrictions were 
imposed, and references of the selected studies were checked for additional relevant citations.
Results: In concordance with the universal trend in mechanical circulatory support, continuous flow devices 
appear to have particular benefits in the elderly. In addition, the literature suggests that early intervention 
before the development of cardiogenic shock, important in all patients, is particularly paramount in older 
patients.
Conclusions: The ongoing refinement of patient selection, surgical technique, and post-operative care will 
continue to improve surgical outcomes, and absolute age may become a less pivotal criterion for mechanical 
circulatory support. However, clear guidelines for the use of mechanical circulatory support in the elderly 
remain undefined.
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Introduction
Since the dawn of the modern era of cardiac surgery and 
the first clinical use of cardiopulmonary bypass in 1953, 
the indications and applications for mechanical circulatory 
support have grown tremendously. The 1960s yielded 
the first successful pneumatic left ventricular assist device 
(LVAD), implanted by Dr. DeBakey, as well as the first 
human heart transplant. Shortly thereafter, mechanical 
circulatory support was being utilized not only to facilitate 
recovery in patients suffering from post-cardiotomy shock 
but to potentially bridge them to transplantation. The high 
mortality of early cardiac transplantation and the severe 
limitations of the first generation extracorporeal LVADs 
led the National Institutes of Health and pioneering 
researchers of the 1970s and 1980s to redouble efforts 
to develop durable implantable assist devices intended 
for use in chronic heart failure (1). Decades of hard work 
and radical innovation to pump design resulted in the 
landmark REMATCH trial in 2001, which demonstrated 
the superiority of mechanical circulatory support to optimal 
medical management for transplant ineligible patients 
with chronic heart failure, and led to FDA approval of the 
pulsatile HM XVE for permanent destination therapy in 
2003 (2). While ultimately supplanted by continuous flow 
devices, this study permanently unchained mechanical 
circulatory support from transplant eligibility and has 
resulted in a sizable and growing population of patients 
receiving lifetime LVAD support. It also brought into 
question the validity of using the age of 70, the arbitrary 
threshold at which most transplant centers will no 
longer consider a patient eligible for transplant, as a 
contraindication to mechanical circulatory support.
According to the most  recent American Heart 
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Association update, an estimated 5.1 million American 
adults have heart failure. Their projections show that 
the prevalence will increase by 46% from 2012 to 2030, 
resulting in greater than eight million Americans suffering 
from heart failure and a steep increase in the incidence with 
each decade of life beyond 65 years (3). With its widespread 
acceptance as a destination therapy, coupled with dramatic 
advances in device design and patient management, 
mechanical circulatory support provides an attractive 
therapeutic option for an ever expanding pool of elderly 
heart failure patients. However, clear guidelines for the use 
of mechanical circulatory support in the elderly have yet 
to be delineated and justification for the use of continuous 
flow devices in older patients will depend upon whether 
it provides superior, cost-effective outcomes compared to 
optimal medical therapy.
Outcomes
Much of the early data on mechanical circulatory support in 
elderly patients are small-sample, single-center, retrospective 
analyses that may not be immediately translatable to the 
modern era of circulatory support, due to their wide use of 
pulsatile VADs and multiple outdated platforms. Despite 
these methodological issues, it has been demonstrated that 
implantation of non-pulsatile systems results in a significantly 
higher survival rate in elderly patients when compared to 
pulsatile systems (4). Furthermore, patients over the age of 
65 years who are implanted with contemporary continuous 
flow LVADs can achieve excellent long term survival, 
compared to predicted medical survival (5).
In recent years, an effort has been made to undertake 
more population-based analyses to better understand both 
the outcomes of mechanical circulatory support in patients 
of advanced age, as well as identify unique predictors of 
morbidity and mortality. Utilizing the Healthcare Cost and 
Utilization Project-Nationwide Inpatient Sample (HCUP-
NIS) registry, the largest all-payer database in the United 
States with over 1,000 participating hospitals, Kilic et al. (6) 
analyzed a total of 2,787 patients aged 60-69 years and 1,472 
patients aged ≥70 years who underwent VAD implantation 
between 2003 and 2008. They found that unadjusted 
mortality rates were comparable between elderly and control 
patients (aged 60-69 years) in both primary support (35.7% 
vs. 32.1%, P=0.61) and post-cardiotomy support (58.1% 
vs. 56.1%, P=0.70). Also, in risk-adjusted multivariable 
logistic regression analysis, age >70 years did not exert an 
independent effect on inpatient mortality, which may be 
partially explained by choosing a somewhat older subset of 
patients as a control group.
In a retrospective analysis of all patients in the 
INTERMACS national registry that underwent implantation 
of a continuous flow LVAD from June 2006 to April 2012 
(greater than 5,000 patients), Atluri et al. (7), utilizing Cox 
proportional hazard multivariable analysis, found that age 
greater than 70 was an independent risk factor for death. 
However, it was noted that, while slightly less than the 
control group, patients aged 70 years or greater had excellent 
overall survival (75% at one year, 63% at two years, 54% at 
three years). This data was congruent with the most recent 
and fifth INTERMACS annual report, which states that 
current survival for all patients (greater than 95% of whom 
received continuous flow devices) is approximately 80% 
at one year and 70% at two years. They also found that 
older age is a risk factor for early mortality, although the 
actuarial survival of patients aged older than 70 years is only 
modestly inferior to that of patients older than approximately 
50 years. Older age also proved to be a marker for increased 
fragility in patient tolerance for other important risk factors. 
This was demonstrated by the interaction between age and 
INTERMACS level, which revealed reduced tolerance in 
the elderly when LVAD implantation occured during acute 
cardiac decompensation (8).
Discussion
To date, there seems to be several overarching themes that 
can be extrapolated from the data on mechanical circulatory 
support in the elderly. In keeping with the universal trend, 
continuous flow devices appear to have particular benefit 
in this population. Also, it has been shown that early 
intervention before the development of cardiogenic shock, 
important in all patients, is particularly paramount in older 
age patients (9). Additionally, while it seems clear that age 
is an independent predictor of increased mortality, the 
overall survival in elderly patients undergoing mechanical 
circulatory support is quite good. This is especially true 
when juxtaposed with medical therapy. The next step will be 
to parse this population further and discover which patient 
variables predict poor outcomes, as well as to better delineate 
the concept of frailty, which encompasses a vulnerability to 
stress and adverse outcomes. Frailty in elderly mechanical 
circulatory support patients is associated with an increased 
risk of death and may represent a significant patient selection 
consideration. However, no universal definition exists (10). 
Going forward, rigorous preoperative assessment must 
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not focus solely on physiologic parameters and successful, 
discerning patient selection in the elective setting will 
include routine assessment of gait, functional status and 
cognition, degree of caregiver support, and advance care 
planning (11). There is much reason for optimism regarding 
mechanical circulatory support in patients of advanced age. 
The ongoing refinement of device design, patient selection, 
surgical technique, and post-operative care will continue 
to improve outcomes. Furthermore, as the indications and 
contraindications for the use of mechanical circulatory 
support in the elderly become more clearly defined, absolute 
age, while simple to quantify, may become a less pivotal 
criteria not only for assist devices, but also for transplant.
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